Advertisement Pharmaceutical Business review - Page 50 of 5291 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 23, 2026

Boehringer and Envisagenics to develop precision cancer therapies

Boehringer Ingelheim and Envisagenics have entered a research collaboration and option agreement that aims to validate tumour-specific targets for the development of precision therapies in solid tumours.

The partnership intends to validate selected tumour-specific targets for therapies that selectively attack cancer cells while reducing impact. Credit: luchschenF / Shutterstock.com.